Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
Table 2
Anticancer drugs used in the 1st-line treatment of patients advanced or metastatic esophagogastric adenocarcinoma () documented in Therapiemonitor 2006–2013. Indicated is the number of patients receiving the respective drugs in the respective years and/or quarters.
Total number of patients 2006–2009 (%)
Total number of patients 2010 (%)
Total number of patients II.-III. quarter 2011 (%)